This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal
by Kinjel Shah
Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
by Zacks Equity Research
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen
by Zacks Equity Research
Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.
The Zacks Analyst Blog Highlights Pfizer, Shopify, PG&E, Hess and Datadog
by Zacks Equity Research
Pfizer, Shopify, PG&E, Hess and Datadog are part of the Zacks top Analyst Blog.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults
by Zacks Equity Research
Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
by Kinjel Shah
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.
Buy These 5 Year-to-Date Laggards With Solid Near-Term Upside
by Nalak Das
We have narrowed our search to five large-cap stocks that have lagged the market year to date. These are: DDOG, SHOP, PFE, HES, PCG.
5 Value Price-to-Sales Stocks to Supercharge Your Portfolio
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like BTU, PSMT, PFE, BBSI and GBX hold promise.
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
Buy 5 Surging Old Economy Stocks to Tap Market Rally
by Nalak Das
Five old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
4 High Earnings Yield Value Bets as Recession Fears Resurface
by Rimmi Singhi
Unlock your portfolio value by investing in value stocks like WDC, PDD, PFE and GOLD that display impressive earnings yield.
Zacks Investment Ideas feature highlights: Northrop Grumman, Pfizer and Kimberly-Clark
by Zacks Equity Research
Northrop Grumman, Pfizer and Kimberly-Clark have been highlighted in this Investment Ideas article.
Volatility Spikes: 3 Low Beta Stocks to Buy
by Derek Lewis
During periods of heightened volatility, low-beta stocks can provide a valuable layer of defense and a more balanced risk profile.
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Can Pfizer (PFE) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Pfizer (PFE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Are Investors Undervaluing Pfizer (PFE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Company News for Jul 31, 2024
by Zacks Equity Research
Companies in The News Are: PFE, PG, SFM, ADM
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
by Zacks Equity Research
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 33.33% and 1.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.